119 related articles for article (PubMed ID: 35506316)
41. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.
Adelzadeh L; Jourabchi N; Wu JJ
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):846-52. PubMed ID: 25081573
[TBL] [Abstract][Full Text] [Related]
42. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
43. Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab.
Lee SH; Park W; Won Lee S; Kim HA; Choe JY; Lee SH; Lee SS; Park SH; Park MC; Sheen DH; Lee HS; Lee YA; Lee Y; Kim TH
Int J Rheum Dis; 2020 Aug; 23(9):1175-1183. PubMed ID: 32725789
[TBL] [Abstract][Full Text] [Related]
44. Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis.
Chen Z; Zheng X; Wu X; Wu J; Li X; Wei Q; Zhang X; Fang L; Jin O; Gu J
Front Immunol; 2021; 12():700570. PubMed ID: 34539629
[TBL] [Abstract][Full Text] [Related]
45. The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors.
Koo BS; Lim YC; Lee MY; Jeon JY; Yoo HJ; Oh IS; Shin JY; Kim TH
Mod Rheumatol; 2021 Nov; 31(6):1192-1201. PubMed ID: 33494621
[TBL] [Abstract][Full Text] [Related]
46. Regulatory T cells in ankylosing spondylitis and the response after adalimumab treatment.
Liao HT; Lin YF; Tsai CY; Chou CT
Joint Bone Spine; 2015 Dec; 82(6):423-7. PubMed ID: 26188878
[TBL] [Abstract][Full Text] [Related]
47. Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients.
Marsman AF; Kneepkens EL; Ruwaard J; Wei JC; Nurmohamed MT; van Denderen C; van der Horst-Bruinsma IE; Rispens T; Wolbink G
Scand J Rheumatol; 2016 Jul; 45(4):331-4. PubMed ID: 26727457
[No Abstract] [Full Text] [Related]
48. Increased number of Herpes Zoster cases in Brazil related to the COVID-19 pandemic.
Maia CMF; Marques NP; de Lucena EHG; de Rezende LF; Martelli DRB; Martelli-Júnior H
Int J Infect Dis; 2021 Mar; 104():732-733. PubMed ID: 33582367
[TBL] [Abstract][Full Text] [Related]
49. Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report.
Lee JM; Lee SJ
J Korean Med Sci; 2020 Jun; 35(21):e201. PubMed ID: 32476306
[TBL] [Abstract][Full Text] [Related]
50. Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.
Ding X; Zhu R; Wu J; Xue L; Gu M; Miao L
Clin Transl Sci; 2020 May; 13(3):547-554. PubMed ID: 31961477
[TBL] [Abstract][Full Text] [Related]
51. The economic impacts of using adalimumab (Humira
Schofield D; Shrestha R; Cunich M
Int J Rheum Dis; 2018 May; 21(5):1106-1113. PubMed ID: 29611342
[TBL] [Abstract][Full Text] [Related]
52. 20 Post-COVID-19 vaccine-related shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media.
Lee C; Cotter D; Basa J; Greenberg HL
J Cosmet Dermatol; 2021 Jul; 20(7):1960-1964. PubMed ID: 33991162
[No Abstract] [Full Text] [Related]
53. COVID-19 in patients with rheumatological diseases treated with anti-TNF.
Brito CA; Paiva JG; Pimentel FN; Guimarães RS; Moreira MR
Ann Rheum Dis; 2021 May; 80(5):e62. PubMed ID: 32546603
[No Abstract] [Full Text] [Related]
54. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India.
Mehta H; Handa S; Malhotra P; Patial M; Gupta S; Mukherjee A; Chatterjee D; Takkar A; Mahajan R
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e16-e18. PubMed ID: 34547126
[No Abstract] [Full Text] [Related]
55. Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study.
Abu-Rumeileh S; Mayer B; Still V; Tumani H; Otto M; Senel M
J Neurol; 2022 Apr; 269(4):1751-1757. PubMed ID: 34724572
[TBL] [Abstract][Full Text] [Related]
56. Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan.
Kobayashi S; Kashiwagi T; Kimura J
Mod Rheumatol; 2019 Nov; 29(6):1007-1012. PubMed ID: 30221573
[No Abstract] [Full Text] [Related]
57. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
58. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
59. Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.
Ruwaard J; l'Ami MJ; Marsman AF; Kneepkens EL; van Denderen JC; van der Horst-Bruinsma IE; Nurmohamed MT; Wolbink G
Scand J Rheumatol; 2018 Mar; 47(2):122-126. PubMed ID: 28745108
[TBL] [Abstract][Full Text] [Related]
60. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
